Vanda Pharmaceuticals (VNDA) Non-Current Assets (2010 - 2026)

Vanda Pharmaceuticals' Non-Current Assets history runs 17 years deep, the most recent figure standing at $140.4 million for Q1 2026.

• In Q1 2026, Non-Current Assets fell 37.35% year-over-year to $140.4 million; the TTM figure through Mar 2026 stood at $745.5 million (down 13.94% YoY), while the FY2025 annual figure was $141.7 million, down 34.8% from the prior year.
• Non-Current Assets came in at $140.4 million for Q1 2026 at Vanda Pharmaceuticals, down from $141.7 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $233.6 million in Q3 2025 to a low of $105.0 million in Q3 2023.
• A 5-year average of $165.7 million and a median of $141.7 million in 2025 frame the typical range for Non-Current Assets.
• Across the five-year window, Non-Current Assets soared 102.53% in 2024 and plunged 37.35% in 2026, its largest moves.
• Vanda Pharmaceuticals' Non-Current Assets stood at $115.0 million in 2022, then surged by 87.46% to $215.5 million in 2023, then climbed by 0.84% to $217.3 million in 2024, then tumbled by 34.8% to $141.7 million in 2025, then slipped by 0.94% to $140.4 million in 2026.
• According to Business Quant data, Non-Current Assets over the past three periods registered $140.4 million, $141.7 million, and $233.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison